|Adherence, persistence, and medication discontinuation in patients with attention-deficit/hyperactivity disorder–a systematic literature review|
K Gajria, M Lu, V Sikirica, P Greven, Y Zhong, P Qin, J Xie
Neuropsychiatric disease and treatment, 1543-1569, 2014
|The short-term impacts of the Philadelphia beverage tax on beverage consumption|
Y Zhong, AH Auchincloss, BK Lee, GP Kanter
American journal of preventive medicine 55 (1), 26-34, 2018
|Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: a systematic review and meta-analysis of real-world observational studies|
DY Heng, J Signorovitch, E Swallow, N Li, Y Zhong, P Qin, DY Zhuo, ...
PloS one 9 (12), e114264, 2014
|Real-world treatment patterns, overall survival, and occurrence and costs of adverse events associated with first-line therapies for medicare patients 65 years and older with …|
MA Bittoni, A Arunachalam, H Li, R Camacho, J He, Y Zhong, ...
Clinical lung cancer 19 (5), e629-e645, 2018
|Sugar-sweetened and diet beverage consumption in Philadelphia one year after the beverage tax|
Y Zhong, AH Auchincloss, BK Lee, RM McKenna, BA Langellier
International journal of environmental research and public health 17 (4), 1336, 2020
|Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second-Line Therapies for Medicare Patients With Advanced Non–Small …|
A Arunachalam, H Li, MA Bittoni, R Camacho, X Cao, Y Zhong, ...
Clinical Lung Cancer 19 (5), e783-e799, 2018
|Nonlinear trajectory of GFR in children before RRT|
Y Zhong, A Muñoz, GJ Schwartz, BA Warady, SL Furth, AG Abraham
Journal of the American Society of Nephrology 25 (5), 913-917, 2014
|Cost-effectiveness of pembrolizumab for patients with advanced, unresectable, or metastatic urothelial cancer ineligible for cisplatin-based therapy|
K Patterson, V Prabhu, R Xu, H Li, Y Meng, N Zarabi, Y Zhong, R Batteson, ...
European urology oncology 2 (5), 565-571, 2019
|Real‐world medication persistence with single versus multiple tablet regimens for HIV‐1 treatment|
D Sweet, J Song, Y Zhong, J Signorovitch
Journal of the International AIDS Society 17, 19537, 2014
|Survival rates and health care costs for patients with advanced bladder cancer treated and untreated with chemotherapy|
K Flannery, X Cao, J He, Y Zhong, AY Shah, AM Kamat
Clinical Genitourinary Cancer 16 (4), e909-e917, 2018
|The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas|
AR Macalalad, M McAuliffe, H Yang, A Kageleiry, Y Zhong, EQ Wu, ...
Current Medical Research and Opinion 31 (3), 537-545, 2015
|The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States|
RL Slater, Y Lai, Y Zhong, H Li, Y Meng, BH Moreno, JL Godwin, T Frenkl, ...
Journal of Medical Economics 23 (9), 967-977, 2020
|Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma|
AG Bensimon, Y Zhong, U Swami, A Briggs, J Young, Y Feng, Y Song, ...
Current medical research and opinion 36 (9), 1507-1517, 2020
|Physician experiences and preferences in the treatment of HR+/HER 2− metastatic breast cancer in the United States: a physician survey|
PL Lin, Y Hao, J Xie, N Li, Y Zhong, Z Zhou, JE Signorovitch, EQ Wu
Cancer Medicine 5 (2), 209-220, 2016
|Cost-effectiveness of pembrolizumab as second-line therapy for the treatment of locally advanced or metastatic urothelial carcinoma in Sweden|
T Srivastava, VS Prabhu, H Li, R Xu, N Zarabi, Y Zhong, JM Pellissier, ...
European urology oncology 3 (5), 663-670, 2020
|Costs of care for patients receiving chemotherapy for advanced bladder cancer|
AM Kamat, X Cao, J He, Y Zhong, AY Shah, K Flannery
J Clin Pathways 3 (10), 63-70, 2017
|Are price discounts on sugar-sweetened beverages (SSB) linked to household SSB purchases?–a cross-sectional study in a large US household and retail scanner database|
Y Zhong, AH Auchincloss, MF Stehr, BA Langellier
Nutrition journal 20 (1), 1-12, 2021
|Everolimus use and associated factors among post-menopausal women with hormonal receptor positive/human epidermal growth factor receptor 2 negative metastatic breast cancer|
N Li, Y Hao, J Xie, PL Lin, Z Zhou, Y Zhong, JE Signorovitch, EQ Wu
Current Medical Research and Opinion 31 (8), 1573-1582, 2015
|Health resource use and costs of vilazodone and other selective serotonin re-uptake inhibitors in treating major depressive disorder|
ZY Zhou, S Sun, P Chopra, Y Zhong, T Totev, J Signorovitch
Journal of Medical Economics 18 (11), 919-929, 2015
|Real world treatment costs and resource utilization among patients with metastatic bladder cancer|
K Flannery, X Cao, J He, Y Zhong, AY Shah, A Kamat
Annals of Oncology 28, v400, 2017